Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05046444 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05046444 · ClinicalTrials.gov record · last posted 2024-12-17

Solving Riddles Through Sequencing

Study acronym: SIRIUS
StatusRecruiting
PhaseNot specified
Started2022-01-19
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 17, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
During the last decades hematologists have excelled at improving and refining the classification, diagnosis, and thus ultimately the therapeutic decision-making process for their patients. This continuous evolution proceeded in parallel to seminal discoveries in basic science such as FISH, PCR and NGS. So far, the current WHO classification serves as reference to diagnostic decision making and is largely based on 5 diagnostic pillars: cytomorphology of peripheral blood and/or bone marrow smears, histology and immunohistochemistry of bone marrow trephine biopsies or lymph nodes, immunophenotyping, chromosome banding analysis supplemented by FISH analysis, molecular genetics including PCR and targeted panel sequencing via NGS. This leads to a swift diagnosis in 90 % of all cases. The leftover 10 % remain a challenge for hematopathologists and clinicians alike and are resolved through interdisciplinary teams in the context of specialized boards. With the advent of high throughput sequencing (mainly WGS and WTS) the possibility of a comprehensive and detailed portrait of the genetic alterations - specifically in challenging cases - has become a realistic alternative to classical methods. In SIRIUS the investigators will prospectively challenge this hypothesis to address the question of how often a better or final diagnosis can be delivered by WGS and/or WTS and if unclear cases can be efficiently resolved.

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2021-09-15; most recent amendment 2024-12-14. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-01-19
Status change Not Yet RecruitingRecruitingv1
Trial Details
NCT Number NCT05046444
Lead Sponsor Munich Leukemia Laboratory
Collaborators: Illumina, Inc.
Conditions Leukemia, Hematologic Malignancy, Rare Diseases, Refractory Leukemia, Refractory Lymphoma, Unknown Primary Tumors
Enrollment 100 participants
Start Date 2022-01-19
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-17